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Abstract: Right-sided heart failure—often caused by elevated pulmonary arterial pressure—
is a chronic and progressive condition with particularly high mortality rates. Recent studies and
our current findings suggest that components of Wild garlic (Allium ursinum, AU) may play a role
in reducing blood pressure, inhibiting angiotensin-converting enzyme (ACE), as well as improving
right ventricle function in rabbit models with heart failure. We hypothesize that AU may mitigate
cardiovascular damage caused by pulmonary arterial hypertension (PAH) and has value in the
supplementary treatment of the complications of the disease. In this present investigation, PAH was
induced by a single dose of monocrotaline (MCT) injection in Sprague-Dawley rats, and animals were
divided into 4 treatment groups as follows: I. healthy control animals (Control group); II. pulmonary
hypertensive rats (PAH group); III. pulmonary hypertensive rats + daily sildenafil treatment
(Sildenafil group); and IV. pulmonary hypertensive rats + Wild garlic liophylisate-enriched chow
(WGLL group), for 8 weeks. Echocardiographic measurements were obtained on the 0 and 8 weeks
with fundamental and Doppler imaging. Isolated working heart method was used to determinate
cardiac functions ex vivo after thoracotomy on the 8th week. Histological analyses were carried out
on excised lung samples, and Western blot technique was used to determine Phosphodiesterase type
5 enzyme (PDE5) expression in both myocardial and pulmonary tissues. Our data demonstrate that
right ventricle function measured by echocardiography was deteriorated in PAH animals compared
to controls, which was counteracted by AU treatment. Isolated working heart measurements
showed elevated aortic flow in WGLL group compared to PAH animals. Histological analysis
revealed dramatic increase in medial wall thickness of pulmonary arteries harvested from PAH
animals, but arteries of animals in sildenafil- and WGLL-treated groups showed physiological status.
Our results suggest that bioactive compounds in Allium ursinum could have beneficial effects in
pulmonary hypertension.
Keywords: Allium ursinum; pulmonary arterial hypertension; phosphodiesterase; sildenafil;
monocrotaline
Int. J. Mol. Sci. 2017, 18, 1436; doi:10.3390/ijms18071436 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2017, 18, 1436 2 of 19
1. Introduction
Right-sided heart failure—often caused by pulmonary hypertension resulting from elevated
arterial pressure—is a chronic and progressive condition with particularly high mortality rates.
Pulmonary arterial hypertension (PAH) is a vascular dysfunction characterized by abnormalities
of endothelial and smooth muscle cells of pulmonary vessels. As a result of the processes, vascular
resistance increases, which quickly starts depleting compensatory mechanisms in the right ventricle.
This maladaptation eventually leads to irreversible damage of the cardiovascular system and premature
death of patients suffering from the disease. PAH itself essentially represents a vasculopathy, and a chronic,
progressive disease entity. This is reflected in the current etiology and pathophysiology-based clinical
classification by the World Health Organization (WHO) of the types of pulmonary hypertension (PH),
where PAH represents one individual group [1].
The condition is predominantly characterized by progressively-increasing vascular resistance
(PVR) of pulmonary arteries. Since the right ventricle is highly sensitive to changes in afterload,
adaptive mechanisms to increased pressure—such as Frank-Starling mechanism and ventricular
muscle hypertrophy—appear in early stages of the disease [2]. Increased tension in chordae tendinae
and dilatation of the annulus leads to tricuspid regurgitation, resulting in dilation of the right atrium,
right ventricular volume overload and decreased cardiac output [3]. Ischemic lesions also appear due
to worsening hypethrophy. The interventricular septum becomes thinner and is even pressed into the
left side of the heart, thereby reducing the volume of the left ventricle during diastole. The processes
necessarily result in decreased cardiac output caused by abnormal reduction of the left ventricular
preload. This vicious circle ends in systemic hypoxia, severe heart failure and premature death [4].
The first line of underlying pathological processes in PAH is vasoconstriction of pulmonary
arteries caused by an imbalance of vasoconstrictor and vasodilator mediators. Multiple dysregulated
signalling pathways have been identified in PAH patients, and a significant portion of disease-specific
therapeutic agents have an influence on the course of the disease through these routes, namely the
nitric oxide (NO) pathway (I), the prostacyclin (II) and endothelin-1 pathways (III) [5–8].
Evidences include decreased NO synthase expression and abnormally high arginase enzyme
levels in lungs of PAH patients, as well as overexpression of phosphodiesterase type 5 enzyme (PDE5),
therefore reduced cyclic guanosine monophosphate (cGMP) levels [9,10]. Further studies have shown
decreased levels of prostacyclin (PGI2) and cyclic adenosine monophosphate (cAMP) in the relevant
tissues, which is partly explained by the fact that the expression of prostacyclin synthase is abnormally
low in the lungs of these patients [11,12].
Endothelin-1, acting on ETA and ETB receptors, is a vasoactive mediator with concominant
proliferative effects on smooth muscle cells in the vessel wall. Under physiological conditions, when
endothelium is intact, activation of ETB receptors increases the production of NO and PGI2. However,
in PAH patients, the ETA receptor pathway overwhelms these effects, causing vasoconstriction by
increasing intracellular calcium levels and activation of protein kinase C enzyme (PKC), as well as
inducing proliferation via the MAPK (mitogen-activated protein kinase) pathway in smooth muscle
cells of pulmonary vessels. Elevated endothelin-1 levels were identified in affected pulmonary tissues,
and the peptide is presented in higher concentrations in PAH patients compared to healthy controls.
Moreover, strong correlation has been found in the levels of endothelin-1 and the degree of pulmonary
hypertension [13,14].
The first modern therapeutic approach based on the previous facts, was to elevate cGMP levels in
the lung, since the required vasodilation caused by NO is mediated by cGMP as a secondary messenger.
Since therapeutic admininstration of nitric oxide itself by inhalation is possible but very inconvenient,
elevation of cGMP level is more feasible by blocking its metabolization through the inhibition of PDE
enzymes. Phosphodiesterase type 5 is the dominant enzyme isoform in the lung that converts cGMP
into guanosine monophosphate (GMP), and thus blocking this isoenzyme prevents cGMP breakdown
and elevates its intracellular levels [15]. PDE5 has also been found to be overexpressed in pulmonary
tissue samples of PAH patients. PDE5 inhibitors (PDE5I) increase the activity of NO-cGMP pathways,
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and thereby promote vasodilation and even have antiproliferative effects on smooth muscle cells of
pulmonary vessels. Sildenafil-citrate, the former blockbuster PDE5I for therapy of erectile dysfunction,
was approved by the FDA (U.S. Food and Drug Administration) to treat pulmonary hypertension in
the year 2005 [16,17]. Sildenafil has clear benefits in PAH, however, the FDA warns about its long-term
use in children because of elevated risk of mortality as revealed in the STARTS-2 trial [18].
Wild garlic (Allium ursinum L.), a plant distributed widely in Eurasia and also known as bear’s garlic or
buckrams, is a popular dietary component, spice and also an element of traditional medicine. Unfortunately,
wild garlic, due to the similarity of the leaves, can easily be mistaken with Colchicum autumnale,
a toxic, colchicine-containing plant, thus some case-studies report rare, but serious poisonings [19].
The herb has a garlic-like scent due to sulfur-containing compounds and also contains high levels
of polyphenol derivatives, mostly flavonoid glycosides [20]. The majority of pharmacological
properties of the plant extract or liophylisate are comparable to those of the close relative, cultivated
garlic (Allium sativum), however, some effects of wild garlic are superior or unique, possibly due
to the presence of some specific components, such as phytosterols and a galactolipid-derivative
(1,2-di-O-α-linolenoyl-3-O-β-D-galactopyranosyl-sn-glycerol). This component seems to be specific for
Allium ursinum and may be absent in other Allium species [21].
While a large amount of data is available on the characteristics of A. sativum, possible therapeutic
effects of A. ursinum are poorly studied, and only a few publications have investigated pharmacological
properties of this plant. Antiaggregatory effects on human platelets are well-proven [21,22], as well
as significant in vitro inhibition of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX) enzymes [23].
Bioactive components of wild garlic have fairly high antioxidant and free radical scavenger activity,
mainly due to superoxide-dismutase, catalase and peroxidase activity of the bulb and leaves [24].
Wild garlic extracts containing ajoene, methyl-ajoene, allicin, diallyl-disulfide have also shown marked
inhibition on cholesterol biosynthesis in vitro, equivalently to cultivated garlic [25]. Allium ursinum
preparations reduce blood pressure and inhibit angiotensin-converting enzyme (ACE) in vivo when
tested on spontaneously hypertensive (SHR) rats [26,27]. Capability of ACE inhibition has been
further evidenced by other studies, where angiotensin-converting-enzyme inhibitor (ACEI) activity of
wild garlic was even found to be superior than such effect of regular garlic [25]. Antihypertensive,
cholesterol-lowering, and ACEI effects contribute to cardioprotection, and such property of the plant
was investigated in a rat model of ischemia/reperfusion injury. Hearts of rats treated with wild
garlic extract showed reduced incidence of ventricular fibrillation and tachycardia with decreased
ischemic areas in myocardial tissues [28]. In a rabbit model of hypercholesterolemia-induced heart
failure, our research team previously demonstrated that supplementation with Wild garlic improves
right ventricle systolic function measured by tricuspid annular plane systolic excursion (TAPSE) [29].
Moreover, studies suggest that bioactive saponines and flavonoids of other Allium species (A. chinese,
A. cepa) have phosphodiesterase enzyme (PDE 5A) inhibitor properties [30,31]. According to the
aforementioned findings, we hypothesize that bioactive components of Allium ursinum may have
benefit in the treatment of pulmonary hypertension, due to possible effects on phosphodiesterase
enzyme system in myocardial and pulmonary tissues.
2. Results
2.1. Mass Spectrometry
The quasi molecular ions cationized by potassium and sodium were observed. It can be assumed
that, based on the the mass of [M + K]+ or [M + Na]+ peaks, the following compounds may be present
in the plant, as seen in Table 1: kaempferol-3-O-rutinoside (at m/z 617.4 [M + Na]+ and m/z 633.3
[M + K]+); quercitrin (at m/z 471.2 [M + Na]+ and m/z 487.2 [M + K]+); juglanin at m/z 441.4 [M + Na]+
and m/z 457.3 [M + K]+; dracorubin (at m/z 511.2 [M + Na]+ and m/z 527.2 [M + K]+); and blumeatin
(at m/z 325.2 [M + Na]+, m/z 341.2 [M + K]+ and m/z 303.1 [M + H]+).
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Table 1. Mass spectrometric analysis of the Wild garlic (Allium ursinum) samples. Table 1 shows
measured and exact m/z values of the main compounds present in A. ursinum leaf liophylisate.
Structure PubChemCID Common Name
Input
m/z
Exact
m/z ∆ Formula Ion
74640 24211973 Kaempferol-3-O-rutinoside 617.4 617.1472 0.2528 C27H30O15Na [M + Na]+
74640 24211973 Kaempferol-3-O-rutinoside 633.3 633.1212 0.1788 C27H30O15K [M + K]+
46189 5280459 Quercitrin 471.2 471.0898 0.1102 C21H20O11Na [M + Na]+
46189 5280459 Quercitrin 487.2 487.0637 0.1363 C21H20O11K [M + K]+
47726 5748554 Juglanin 441.4 441.0792 0.3208 C20H18O10Na [M + Na]+
47726 5748554 Juglanin 457.3 457.0531 0.2469 C20H18O10K [M + K]+
68247 160270 Dracorubin 527.2 527.1255 0.0745 C32H24O5K [M + K]+
68247 160270 Dracorubin 511.2 511.1516 0.0484 C32H24O5Na [M + Na]+
48987 11289628 Blumeatin 341.2 341.0422 0.1578 C16H14O6K [M + K]+
48987 11289628 Blumeatin 325.2 325.0683 0.1317 C16H14O6Na [M + Na]+
Calculations were made on the basis of molar mass of the K and Na adducts. The exact molar mass
of each compound was calculated as follows: measured m/z minus the molar mass of the adducted
ion equals the molar mass of the compound.
2.2. Echocardiography
All echocardiographic examinations were completed within a 20-min time interval, and all animals
managed to recover from the anesthesia with stable heart rates and respiratory frequencies during the
whole procedure. As seen in Table 2, Fractional Shortening (FS) and Ejection Fraction (EF) values did
not show any changes among groups. Systolic function estimated by measuring mitral annular plane
systolic excursions (MAPSE) showed no changes among treatment groups, a result also observed for
Heart rate (HR).
Table 2. Echocardiographic data of the four rat test groups in the study. Right ventricle function was
estimated using tricuspid annular plane systolic excursion (TAPSE). Significant decreases were found
in TAPSE values of PAH (pulmonary arterial hypertension) group animals compared to the Controls.
Values for animals receiving sildenafil injection and Wild garlic (Allium ursinum) liophylisate-enriched
chow (WGLL) were elevated in comparison to the PAH group.
Parameter Control PAH Sildenafil WGLL
LV Ejection Fraction (%) 73.39 ± 3.638 82.61 ± 2.911 76.93 ± 2.294 76.13 ± 2.327
LV Fractional Shortening (%) 38.64 ± 3.268 47.75 ± 3.432 40.84 ± 2.177 40.49 ± 2.059
LV mass (g) 1.388 ± 0.085 1.343 ± 0.037 1.487 ± 0.036 1.469 ± 0.057
Stroke volume (mL) 0.459 ± 0.070 0.456 ± 0.056 0.445 ± 0.081 0.452 ± 0.032
HR (bpm) 269.5 ± 16.21 274.2 ± 9.37 264.3 ± 10.39 243.1 ± 9.76
LVOT maxPG (mmHg) 2.225 ± 0.247 2.415 ± 0.260 2.401 ± 0.381 2.128 ± 0.179
LVOT meanPG (mmHg) 1.032 ± 0.112 1.067 ± 0.096 1.169 ± 0.185 0.876 ± 0.074
LVOT Vmax (m/s) 0.753 ± 0.041 0.746 ± 0.445 0.748 ± 0.082 0.720 ± 0.032
LVOT Vmean (m/s) 0.432 ± 0.025 0.451 ± 0.018 0.463 ± 0.045 0.398 ± 0.017
Lat S’ (cm/s) 32.29 ± 1.782 40.51 ± 2.710 50.39 ± 2.278 * 39.36 ± 3.565
MV E vel (cm/s) 65.81 ± 3.860 64.71 ± 3.046 58.09 ± 2.906 63.56 ± 2.484
MV A vel (cm/s) 40.15 ± 4.253 37.54 ± 5.484 30.82 ± 1.054 39.19 ± 2.385
MV E/A ratio 1.841 ± 0.167 1.856 ± 0.165 1.903 ± 0.052 1.745 ± 0.129
MAPSE (mm) 2.085 ± 0.089 1.961 ± 0.098 1.905 ± 0.057 1.944 ± 0.150
TAPSE (mm) 2.308 ± 0.074 1.697 ± 0.098 * 2.390 ± 0.069 # 2.021 ± 0.071 #
* p < 0.05 compared to Control; # p < 0.05 compared to PAH.
Estimation of right ventricle systolic function was attainable by measuring TAPSE (tricuspid
annular plane systolic excursion) values. TAPSE parameters of Control animals remained at normal
range (TAPSEControl: 2.308 ± 0.074 mm), but significant decreases were found in values of PAH group
animals (TAPSEPAH: 1.697 ± 0.098 mm) compared to the Controls. Values of WGLL-treated and
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sildenafil-treated animals were elevated in comparison to PAH group (TAPSEWGLL: 2.021 ± 0.071 mm,
and TAPSESildenafil: 2.390 ± 0.069 mm, versus TAPSEPAH: 1.697 ± 0.098 mm).
Diastolic function of the left ventricle was estimated using Doppler (PW) techniques, by determining
E/A ratios at the mitral valve. E/A ratios were unaffected either by monocrotaline-injection, or by sildenafil-
or WGLL-treatment after 8 weeks.
2.3. Effects of Monocrotaline (MCT) and Treatments on Isolated Left Ventricular Function
Results of LV function obtained by isolated working heart method are shown in Figure 1.
Monocrotaline treatment produced reduction in aortic flow (AF) compared to the Control group
(AFPAH: 27.38 ± 3.447 mL/min vs. AFControl: 55.33 ± 2.932 mL/min), and aortic flow of animals after
WGLL treatment reached the Control values (AFWGLL: 54.36 ± 2.864 mL/min). Coronary flow (CF)
and Aortic pressure (AoP) were observed to be unaffected by the treatments (p < 0.05). Heart rate of
isolated hearts increased in WGLL-treated animals (HRWGLL: 327.5 ± 28.22 bpm) in comparison to
Control group (HRControl: 224.0 ± 5.579 bpm).
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0.05 compared to Control; # p < 0.05 compared to PAH. AF, CO and SV values of PAH animals were 
decreased compared to controls, whereas CO was found to be elevated in sildenafil and WGLL groups 
compared to PAH group. AF values of WGLL animals were increased in comparison to PAH animals. 
2.4. Body Mass 
We observed no significant differences in body weights among groups, when measured at the 
endpoint of the study (Control: 485.5 ± 18.40 g; PAH: 502.6 ± 17.79 g; Sildenafil: 443.9 ± 17.10 g; and 
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Histological examinations of HE-stained heart tissue sections from rats are shown in Figure 2. 
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Sildenafil-injected group, and Wil garlic (Allium ursinum) liophylisate-enriched chow (WGLL) group.
Results are shown as average values for each group of rats ± standard error of the mean (SEM) for
aortic flow (AF, mL/min, A); coronary flow (CF, mL/min, B); aortic pressure (AoP, Hgmm, C); heart
rate (HR, beat/min, D); cardiac output (CO, mL/min, E); and stroke volume (SV, mL, F). * p < 0.05
compared to Control; # p < 0.05 compared to PAH. AF, CO and SV values of PAH animals were
decreased compared to controls, whereas CO was found to be elevated in sildenafil and WGLL groups
compared to PAH group. AF values of WGLL animals were increased in comparison to PAH animals.
2.4. Body Mass
We observed no significant differences in body weights among groups, when measured at the
endpoint of the study (Control: 485.5 ± 18.40 g; PAH: 502.6 ± 17.79 g; Sildenafil: 443.9 ± 17.10 g;
and WGLL: 448.2 ± 10.36 g). A limitation of this study is that the effects of Allium ursinum
supplementation on food and water consumption were not measured.
2.5. Microscopic Morphometry
Histological examinations of HE-stained heart tissue sections from rats are shown in Figure 2.
Right and left ventricle (RV + LV) sections staine with HE showed clear signs of tissue damage in all
MCT-trea ed g oups (PAH, WGLL, Sildenafil gr ups), w er as the Control group is morphologically
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normal (Figure 2B). Tissue damage in PAH group samples is characterized by contractures of
cardiomyocites, hyperbasophilia, hypereosinophilia, wavy arrangement of myofibers, cell edema,
lesion and apoptosis of cardiomyocytes. Samples of PAH group show the most dramatic RV
hypertrophy in myocardial structure, meanwhile only moderate macroscopic hypertrophy is visible
in WGLL-treated RV tissues compared to PAH group. Lung samples of all animals were evaluated
by HE- and EVG stains as shown in Figure 2C,D. Right vetricular hypertrophy (RVH) was presented
as RV/(LV + S) ratio, as seen in Figure 2E. RV/(LV + S) ratio was increased in PAH group
(0.477 ± 0.044) compared to Control (0.323 ± 0.020) and WGLL (0.328 ± 0.020) groups. Medial wall
thickness percentage (MWT %) was determined in pulmonary arteries/arterioles (<50 µm diameter)
of each group by using the equation: % MWT = (M1 + M2)/ED × 100. Medial wall thickness
increased in PAH animals when compared to all other groups (% MWTPAH: 71.39 ± 2.628% vs. %
MWTControl: 53.64 ± 3.240%; % MWTWGLL: 47.32 ± 2.084%, and % MWTSildenafil: 48.91 ± 3.444%).
We observed no differences in values of WGLL- and Sildenafil-treated animals compared to the Control
group (Figure 2F).
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2.6. Western Blot
The levels of PDE5A enzyme expression in right ventricular and lung tis sues are presented in
Figure 3A,B. When measured in cardiac tissues, expression of PDE5A in PAH and WGLL groups was
elevated compared to levels detected in Sildenafil and Control groups (PAH: 2.174 ± 0.110 and WGLL:
2.690 ± 0.096 vs. Sildenafil: 1.432 ± 0.139 and Control: 1.410 ± 0.088). Additionally, sildenafil
treatment showed marked inhibition of PDE5A expression in RV tissue. There were no changes
observed in values of WGLL and PAH groups from right vetricle homogenates. In contrast, PDE5
expression levels in MCT-treated lung tissues showed no differences when compared to Control group,
however, a significant increase was observed in WGLL in comparison to PAH group animals (Control:
1.367 ± 0.189; WGLL: 2.329 ± 0.094; Sildenafil: 1.968 ± 0.209 vs. PAH: 1.029 ± 0.079; in arbitrary units).
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Figure 3. Western blot results from rats receiving four treatments: PAH (pulmonary arterial
hypertension), WGLL (Wild garlic (Allium ursinum) liophylisate-enriched chow), Sildenafil injection,
and Control. (A) shows quantified results of Western blot analysis after normalization to
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and data are presented as mean ± SEM
for each treatment group. RV = right ventricle, L = lung (n = 9; * p < 0.05); and (B) shows PDE5A
expression in right ventricles (RV) and in lung tissues (L). * p < 0.05 compared to Control; # p < 0.05
compared to PAH;
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3. Discussion
One accomplishment of this present study is characterizing the flavonoid content of Allium
ursinum leaves, liophylised by the method used for our standard investigations, and comparing it
to data available in literature, where chemical constituents were determined from fresh leaves [20].
Our results are well-correlated with previous findings [32], since the dry liophilysate contains several
phenolic compounds, i.e., kaempherol derivatives, juglanin, dracorubin, blumetain and quercitrin
(as seen in Figure 4 and Table 1); thus we successfully demonstrated that Allium ursinum is exceptionally
rich in flavonoid compounds. These outcomes have high value, because if a natural product is intended
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to be used for therapeutic purposes according to evidence-based medicine, investigators need to be
aware of its main components and their chemical structure. Furthermore, many pharmacological
studies have confirmed the fact that these polyphenols have high potential in prevention and treatment
of several disorders [33–35].
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previously separated by C18 column; (A) Compounds with relatively low molecular weight;
B: compounds with higher molecular weight; (C,D) components of WGLL extract, previously separated
by silica S100 column; (C) Compounds with relatively low molecular weight; (D) Compounds with
higher molecular weight.
Echocardiographic data revealed that after 8 weeks of treatment, deterioration was not observed
in left ventricular diastolic or systolic functions of pulmonary hypertensive or either WGLL- or
sildenafil-treated animals. Tricuspid annular plane systolic excursion (TAPSE) correlates well with
right ventricular dysfunction in heart failure patients, and can be easily determined by using M-mode
echocardiography. TAPSE parameters were reduced in pulmonary hypertensive rats, but improved
after 8 weeks of WGLL treatment. Our findings support the results of other experiments; for instance,
Rajkumar et al. showed very similar TAPSE values of MCT-induced PAH rats (around 1.6 mm), as well
as healthy animals (above 2 mm) [36]. According to our former and recent findings, Allium ursinum
liophylisate treatment improves right ventricular function in hypercholesterolemic rabbits [29], as well
as in a rat model of MCT-induced pulmonary hypertension. A limitation of this current study is that
we failed to consequently visualize pulmonary artery and measure parameters such as pulmonary
arterial pressure, acceleration time and pulmonary ejection time by echocardiography, as hallmarks of
PAH, formerly described by Thibault et al. [37]. Our disease model was evidenced by other techniques,
e.g., measuring medial wall thickness of pulmonary arteries after histological staining.
Isolated working heart is a widespread and well-known method for studying cardiac functions
without the innervation of autonomic nervous system [38,39], and our workgroup carried out many
experiments based on this method [29,40,41]. Echocardiographic and isolated heart data are often
well-correlated in many cardiac parameters, however, discrepancies can also be observed, due to the
lack of innervation and vegetative and adaptive reflexes in isolated working heart procedures.
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Isolated heart outcomes of the present study (Figure 1) revealed that monocrotaline treatment
decreases aortic flow, which characterizes the pump function of the left ventricle. This finding further
supports several former outcomes of other authors, where monocrotaline induced PAH [42–44], and the
consequential right-heart failure eventually leads to left ventricle failure as well [45]. According to
our results, sildenafil increased cardiac output when compared to PAH group. Consistent with this,
many articles in the scientific literature confirm this finding and verify that sildenafil exerts significant
protection in monocrotaline-induced PAH [46–48]. Comparably, treatment with WGLL also exerted
protection against monocrotaline-induced changes: Allium ursinum improved aortic flow and cardiac
output compared to the PAH group. Nonetheless, an increase in cardiac output was observed in the
WGLL group compared to PAH group; neither heart rate and non stroke volume parameters changed
significantly, due to the power of detection. Despite non-significant changes in aortic flow, cardiac
output parameters of Sildenafil group compared to PAH followed the same pattern. In a previous
work of our team [29], WGLL treatment showed similar effects on isolated heart functional parameters
of hypercholesterolemic rabbits after ischemia/reperfusion injury.
Improvements of left or right ventricular function and aortic flow after WGLL treatment have been
shown on two animal disease models by our team so far, however, underlying molecular mechanisms,
as they seem to be independent from PDE5 system, still require further investigations. Although this
study provides useful background information about the effects of WGLL-supplementation on PDE
system, measuring endothelial nitric oxide synthase (eNOS) activity or cGMP levels would provide
further insights into the potential mechanisms of the protective effect of garlic leaves, which will be
addressed in future studies [49].
In this current study, values of aortic pressure did not show any changes among the treatment
groups. As this method utilizes an isolated organ, only the most severe left ventricle heart failure
could cause aortic pressure changes, i.e., when the myocardium fails to produce the sufficient pressure
on the blood in the ventricle to pump it out [50]. In our current study and experimental conditions,
maybe due to the relatively short time period, the left ventricle failure was not in this developmental
stage, thus we did not observe any changes in this parameter.
The heart rate measurements during isolated heart experiments showed a moderate increase in all
of the monocrotaline-treated groups. Such mild increase in heart rate due to monocrotaline treatment
has been shown by other authors as well [51].
In our isolated working heart experiments, Allium ursinum proved its protecting efficacy again,
comparably to sildenafil in a rat model of PAH: both sildenafil and WGLL treatments improved
cardiac output values compared to the monocrotaline-alone treated group. Furthermore, in the case
of cardiac output, neither of the two differed from values of the healthy control group. Similarly,
Allium ursinum has been shown to be cardioprotective against other, different types of injuries as well,
such as ischemia-reperfusion induced injury [28], and elevated blood pressure [27], thus we consider
wild garlic as a possibly valuable supplement in the therapy of various heart diseases.
Although it has been reported frequently that MCT damages pulmonary endothelial cells,
the exact toxicological mechanisms by which MCT initiates lung toxicity are still obscure, furthermore,
several investigators dispute the relevance of MCT-model in imitating pathobiological processes of the
human disease [52]. Despite this fact, MCT-induced pulmonary arterial hypertension is still the most
favored model in preclinical research in testing novel therapies; moreover, almost all animal models
are imperfect in some way in imitating the patomechanism or manifestation of this disease.
In this work, we demonstrated that MCT-induced pulmonary arterial hypertension caused RV
hypertrophy in animal models, a finding published in previous studies as well [53,54]. Sildenafil has
also been reported to attenuate mean pulmonary artery pressure (PAP), pulmonary vascular resistance
(PVR), and enhance RV functions by inducing changes in gene expression in heart and lung tissues [55].
Our results confirm these findings; furthermore, as reported in microscopic morphometrical findings,
WGLL supplementation demonstrates comparable effects to Sildenafil in alleviating symptoms of
pulmonary arterial hypertension.
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Pulmonary vascular remodeling is the first and critical component of PAH pathogenesis,
with significant involvement of NO/cGMP system. Isoforms of phosphodiesterase enzyme are
responsible for hydrolysis of cGMP in pulmonary vasculature [56]. It was previously demonstrated
that sildenafil promotes accumulation of cGMP, thus prolonging effects of NO via inhibition of PDE5
enzyme [57]. This study confirms the fact that sildenafil inhibits the elevation of PDE5A expression
in right ventricle induced by the disease, affirming previous reports [58]. Upregulation of PDE5 has
been reported in conditions like congestive heart failure, pulmonary hypertension and even right
ventricular hypertrophy, perhaps as a countering mechanism [59]. Our Western blot findings also
verify that in monocrotaline-induced PAH model, expression of PDE5A is highly elevated in the right
ventricle. As shown in Figure 3A, WGLL treatment did not affect raised PDE5A levels in the right
myocardial tissues, and possibly exerts its protective effects via other signalling pathways. According
to our knowledge, this result is unique, since no other research team has studied the impact of Allium
ursinum extracts on the expression of PDE5 enzyme. Furthermore, levels of PDE5 in lung tissues were
elevated after WGLL treatment when compared to the PAH group. Although PDE5A protein levels
did not differ between PAH and Control group when measured in lung tissues, this finding does not
exclude that the activity of the enzyme may be elevated without a simultaneous rise in its expression.
This observation is consistent with previous works, demonstrating that only the phosphorylated form
of PDE5 indicates an increase in PDE activity [60,61]. Incidentally, our investigation was limited to the
measurement of only the unphosphorylated PDE5 protein levels, therefore, we did not observe any
changes in values of Sildenafil-treated group compared to Control group, as reported by others [62].
Although it is well published that elevated levels of PDE5 enzyme are associated with underlying
pathological processes of the disease, we observed no significant deterioration in cardiac functions nor
histological features of WGLL-treated animals when compared to the PAH group (as seen in Figures 1
and 2 and Table 2), which can be partly explained by the fact that many other signaling pathways are
involved in molecular pathogenesis of pulmonary arterial hypertension [63–65].
Despite the fact that Allium sativum (cultivated garlic) is much more characterized and described
in scientific literature, along with previous studies, our recent work suggests that Allium ursinum
is also a valuable herbal product. Moreover, there are a substantial number of comparative reports
in which Allium ursinum exerts even more beneficial effects on disease models compared to Allium
sativum [23,27,66,67]. Last, but not least, Wild garlic is a readily accessible and affordable plant,
distributed widely both in Europe and Asia [68].
In summary, Sildenafil exhibited protective efficacy against monocrotalin-induced pulmonary
arterial hypertension and vascular remodelling, and beneficial effects exerted by WGLL treatment
are well comparable to the standard therapy. Our findings also indicate that it would be feasible to
evaluate synergistic actions of Sildenafil and WGLL supplementation in the treatment of pulmonary
arterial hypertension.
4. Experimental Section
4.1. Sample Liophyilisation and Mass Spectrometry
Liophylisation of Allium ursinum leaves was carried out as previously described by the authors of
this present paper [29].
Mass spectrometry (Matrix-assisted laser desorption/ionization–time of flight, MALDI-TOF
MS) analyses of the compounds were performed in positive-ion mode using a Bruker Biflex III
MALDI-TOF mass spectrometer equipped with delayed-ion extraction (Bruker Daltonics, Bremen,
Germany). Desorption/ionization of the sample molecules was effected with a 337-nm nitrogen laser
with a pulse width of 3 ns. Spectra from multiple (at least 100) laser shots were summarized using
19 kV accelerating and 20 kV reflectron voltages. External calibration was applied using the [M + Na]+
peaks of cyclodextrines DP 6–8 m/z: 995.31, 1157.36, 1319.41 Da, respectively. The spectrum was
obtained from a 2,5-Dihydroxybenzoic acid matrix substance for MALDI-MS, (>99.0% (HPLC), Sigma
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Matrix) by mixing 10 µL of saturated matrix solution in ethanol:water = 1:1 with 10 µL of sample
dissolved in water, then 0.5 µL was applied to the sample target and was allowed to dry at room
temperature. The identification of compounds was done on the basis of the mass of [M + H]+ or
[M + Na]+ peaks. The calculations were based on the database of Metabolomics Workbench Data (“The
Metabolomics Workbench”, http://www.metabolomicsworkbench.org/).
4.2. Study Design
Male rats of the Sprague Dawley strain weighing 200–250 g were purchased from Charles River
International Ltd. (Wilmington, MA, USA). Animals were housed under a 12:12 h light-dark cycle
in a specific pathogen-free environment and had free access to food and water. Body weights were
measured in all animals at the endpoint of the study (8 weeks). PAH was induced by a single
subcutaneous injection of monocrotaline (MCT, 60 mg/kg, to the interscapular region), the specific
toxic alkaloid of Crotalaria spectabilis (Sigma-Aldrich Co., St. Louis, MO, USA) [69], whereas the control
group recieved only the vehicle, Dimethyl sulfoxide buffer (DMSO buffer, Control group, n = 8).
MCT-treated rats were then divided into 3 subgroups as follows: rats that received only MCT injection
and developed PAH (PAH group, n = 8); rats that received MCT injection and were kept on standard
chow enriched with 2% wild garlic leaf liophilizate (WGLL group, n = 8); and MCT-injected rats
that were treated with 25 mg/kg sildenafil daily via oral (gavage technique) dosing (Sildenafil
group, n = 8). Allium ursinum liophylisate-enriched chow was produced in the laboratory of the
Department of Pharmaceutical Technology, University of Debrecen, Hungary. Sildenafil, as well as
all other chemicals used in the preparation of buffer solutions for isolated working heart procedure,
stains and Western blot technique were obtained from Sigma-Aldrich Co. (Budapest, Hungary).
All experimental protocols were approved by the local Ethics Committee of the University of Debrecen
(25/2013DEMÁB, 29 January 2014), and the animals received humane care in accordance with the
“Principles of Laboratory Animal Care” by EU Directive 2010/63/EU for animal experiments.
4.3. Transthoracic Echocardiography (TTE)
Echocardiographic studies were performed using a Vivid E9 sonograph (GE Healthcare,
Little Chalfont, UK) to estimate myocardial functions under light anasthesia with ketamin/xylazine
(50/5 mg/kg) intramuscular injection (i.m.) at the start and endpoint of treatments. The thorax
was shaved and the animals were positioned in a dorsal decubitus position. Images were obtained
using an i13L linear array probe (at 14 MHz) with high temporal and spatial resolution. Complete
2-dimensional, M-mode (at papillary muscle levels), Doppler (PW), and tissue Doppler (TDI)
echocardiograms were acquired and digitally stored for further analysis. Doppler imaging at
the mitral and aortic valves was obtained from the apical 3- and 4-chamber views. ECG was
continously monitored during echocardiographic examinations in all cases. Measurements included
interventricular and left ventricular free-wall thickness in diastole and systole (IVSs, IVSd),
left ventricular internal diameter at end-diastole (LVIDd) and end-systole (LVIDs), and aortic root
diameter (Ao). End-systolic volume (ESV), end-diastolic volume (EDV), stroke volume (SV) and mass
of left ventricle (LV mass) were calculated. Fractional shortening was computed by using the equation
(LVIDd − LVIDs)/LVIDd × 100%, and the ejection fraction (EF) was calculated by computer using the
Teiholz formula. Mitral annular peak systolic excursion (MAPSE) and tricuspidal annular peak systolic
excursion (TAPSE) were assessed with M-mode, measuring the distance of mitral or tricuspid annular
movement between end-diastole to end-systole. From the mitral inflow velocity image (Doppler),
the following measurements were obtained: left ventricular peak E and peak A waves (mitral early and
late filling velocities) and the E to A ratio (E/A). Left ventricle outflow tract (LVOT) parameters were
also determined: maximal- and mean pressure gradients (LVOT maxPG, LVOT meanPG), as well as
maximal- and mean outflow velocities (LVOT Vmax, LVOT Vmean, see Figure 5.). Tissue velocities at
the lateral annulus of mitral valve were estimated using spectral tissue Doppler by determining systolic
(S’) waves. Visualization of the right ventricle and estimation of systolic function by using TAPSE
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was accessible in many rats, however, measuring right ventricle diastolic function was unattainable in
most cases. All measurements were averaged over three to five consecutive cardiac cycles and were
conducted by the same investigator (Bela Juhasz), to avoid interobserver variability. Acquired images
were analyzed by using EchoPAC PC softwave (GE Healthcare, Little Chalfont, UK) by two other
experienced investigators (Daniel Priksz, Mariann Bombicz). Interobserver variability as well as
intraobserver variability was less than 10% in all examinations. The total examination time usually
was less than 15 min; thereafter rats were allowed to recover from the procedure [70].Int. J. Mol. Sci. 20 7, 18, 1436  12 of 18 
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4.4. Isolated Heart Parameters
At the endpoint of the study, animals were anesthetized with an intramuscular ketamin/xylazine
injection (100/10 mg/kg). A bolus of heparin was administered (1000 U/kg of body weight,
intravenously) 15 min before surgery, to avoid thrombosis. Once deep unconsciousness was achieved,
hearts were removed by a subxiphoidal incision following thoracotomy, placed in ice-cold buffer,
and were quickly cannulated and perfused via the aorta using Langendorff apparatus. The elapsed
time between opening the thoracic cavity and onset of perfusion never exceeded 60 s. First, retrograde
perfusion was initiated, at a pressure of 100 cm H2O for 10 min, which allowed time to wash out the
anesthetic. The perfusate was pH 7.4 Krebs-Henseleit bicarbonate buffer, bubbled with Carbogen gas
(95% O2–5% CO2) and containing 118 mM NaCl, 4.7 mM KCl, 1.7 mM CaCl2, 25 mM NaHCO3, 0.36 mM
KH2PO4, 1.2 mM MgSO4, and 10 mM glucose. The left atrium was cannulated during the retrogarde
perfusion via the pulmonary vein. A small incision was made at the bifurcation of pulmonary arteries;
thus all coronary effluent could be collected by the pulmonary artery. Following Langendorff-perfusion,
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the system was switched to working mode and hearts were perfused for 15 min. Heart functions,
assessed by changes in heart rate and peak systolic pressure development, were monitored throughout
the perfusion period using a pressure transducer attached to the aortic outflow line. The following
parameters were recorded: aortic pressure (AoP), heart rate (beats/min). Aortic flow (AF, mL/min)
and coronary flow (CF, mL/min) were measured by using a flowmeter [71]. All surgeries were
performed by the same investigator (Balazs Varga), who was blinded to the treatments, and animals
were randomly sacrificed.
4.5. Histological Evaluation of Myocardial and Lung Tissue Samples
Following isolated working heart procedure, hearts were dissected transversely at mid-LV level
and samples were fixed for 24 h in 4% neutral buffered formalin (pH = 7.4) and further prepared
for paraffin sectioning. From the formalin-fixed, paraffin-embedded (FFPE) blocks, 7 µm thick
sections were created and stained with hematoxylin-eosin (HE) to visualize tissue architecture [72].
RV hypertrophy (RHV) was assesed on a whole transverse section of the heart and was described as
the ratio RV/(LV + interventricular septum (IVS)).
The formalin-fixed, paraffin-embedded left lung sections (7 µm) were stained with HE,
and Elastica van Gieson (EVG) for morphometric analysis of vascular dimensions [73]. The external
diameters of small pulmonary arteries were measured along the shortest curvature. The relative
medial thickness of muscular arteries and lumen-carrying capacity (ranging in size from <50 µm in
external diameter) was calculated with the formula ((external diameter − internal diameter)/external
diameter × 100) (% MWT = (M1 + M2)/ED × 100) in EVG-stained slides (Figure 6). Fifteen arteriole
images per lung section were examined by light microscopy using a Leica DM2500 microscope with
DFC 420 camera and Leica Application Suite V3 software (Leica Camera AG, Solms, Germany).
The microscope slides were analyzed in a blinded fashion and both the size of the lumen and vessel
wall thicknesses were calculated using Scion for Windows Densitometry Image program Version Alpha
4.0.3.2 (Scion Corporation, Frederick, MD, USA).
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4.6. Western Blot
Deep-frozen rat LV and lung tissue samples were homogenized and then boiled in sample
buffer for 10 min. The adjusted final protein concentration was 25 µg mL−1. BCA reagent and BSA
standard were used for protein quantification assay. The separating gel consisted of 30% glycerol,
6% acrylamide-bis, 0.2 mM Tris, 4 mM Ethylenediaminetetraacetic acid (EDTA) and 0.4% Sodium
dodecyl sulfate (SDS) and the polymerization of the gels was induced by ammonium persulfate
(10 m/m%) and tetramethylethylenediamine. The upper running buffer was composed of 0.1 mM Tris,
150 mM glycine and 0.1% SDS, and gel was composed of 50 mM Tris, 75 mM glycine and 0.05% SDS.
Constant voltage (70 V) was used for separation. A prestained molecular weight standard (ProSieve
QuadColor, Lonza; Rockland, MA, USA) was used as loading marker. Separated proteins in the gels
were electrophoretically transferred onto nitrocellulose membrane at 380 mA for 45 min. The blotted
membrane was blocked with 5% low-fat milk in Tris-buffered saline (TBS) containing 1% Tween
20 (TBS-T buffer). After washing the membrane with TBS-T, primary PDE5A and Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) antibodies (Sigma-Aldrich Co., St. Louis, MO, USA) diluted in
TBS-T with 1% low-fat milk were added and incubated overnight at 4 ◦C. All antibodies were indicated
to Western blotting, and were used in dilutions suggested by the manufacturers. The bound antibodies
were detected by horseradish peroxidase-conjugated anti-rabbit Ig secondary antibody followed by
ECL detection (Western Lightning Plus ECL, PerkinElmer; Waltham, MA, USA) and the signals were
recorded by an imaging system (MF-Chemibis 3.2, Central European Biosystems; Budapest, Hungary).
Quantitative analysis of scanned blots was carried out using the Scion for Windows Densitometry
Image program Version Alpha 4.0.3.2 (Scion Corporation). Signal intensity for bands corresponding to
each protein of interest was estimated and reported in arbitrary units ± SEM [74].
4.7. Data Analysis and Statistical Procedures
All data are presented as the average magnitudes of each outcome in a group ± standard error
of the mean (SEM). Statistical analysis was performed using one-way analysis of variance (ANOVA)
with Bonferroni post-testing (when normality test was passed) or by Kruskal–Wallis test with Dunn’s
post-testing (if the normality test was not passed). Statistical analyses were conducted using GraphPad
Prism software for Windows, version 5.01 (GraphPad Software Inc., La Jolla, CA, USA). Probability
values (p) less than 0.05 were considered statistically significant.
5. Conclusions
Our recent paper highlights the possible protective effects of Allium ursinum lyophilisate
supplementation in pulmonary arterial hypertension investigated on a rat model of the disease.
According to our knowledge, this is the first study to evaluate possible benefits of Allium ursinum in
a model of PAH, and to directly compare it with a well-known PDE inhibitor, sildenafil. Our findings
demonstrate that WGLL supplementation exerts protection against MCT-induced pulmonary arterial
hypertension in a rat model, shown by significant changes in either echocardiographic and isolated
heart functions, or histological analyses. Right-heart systolic functions assessed by echocardiography
showed improvements in tricuspid annular plane systolic excursions, while isolated heart experiments
revealed an increase in left ventricle aortic flow and cardiac output. These findings were further
supported by Western blot analyses, where WGLL supplementation did not show any changes
in PDE5A expression levels when compared to values measured in samples harvested from
PAH animals. In contrast, histology revealed that increase in medial wall thickness caused by
monocrotaline-treatment was counteracted by WGLL treatment. Our hypothesis is partly confirmed
experimentally, as supplementation with WGLL, a low-cost and reasonable natural product, suppresses
the symptoms of MCT-induced pulmonary hypertension in a rat model, but its protective effects on
cardiovascular system seem to be independent from the PDE5 pathway; thus underlying mechanisms
need further investigations.
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